Tourmaline Bio, Inc.

NasdaqGS:TRML Stock Report

Market Cap: US$484.5m

Tourmaline Bio Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Sandeep Kulkarni

Chief executive officer

US$848.3k

Total compensation

CEO salary percentage68.97%
CEO tenureno data
CEO ownership2.9%
Management average tenure1.8yrs
Board average tenureless than a year

Recent management updates

Recent updates

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20

We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate

Apr 19
We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Oct 13

Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish

Mar 22

Tourmaline Bio: Time For A Pause

Jan 18

CEO Compensation Analysis

How has Sandeep Kulkarni's remuneration changed compared to Tourmaline Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$83m

Dec 31 2024US$848kUS$585k

-US$73m

Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$3mUS$114k

-US$42m

Compensation vs Market: Sandeep's total compensation ($USD848.25K) is below average for companies of similar size in the US market ($USD2.53M).

Compensation vs Earnings: Sandeep's compensation has been consistent with company performance over the past year.

CEO

Sandeep Kulkarni (43 yo)

no data
Tenure
US$848,250
Compensation

Dr. Sandeep C. Kulkarni, M.D. was Chief Operating Officer of Immunovant, Inc. He serves as Co-Founder, CEO and Director at Tourmaline Bio, Inc. From July to October 2018, he served as Vice President, Speci...

Leadership Team

NamePositionTenureCompensationOwnership
Sandeep Kulkarni
Co-Founderno dataUS$848.25k2.87%
$ 13.9m
Ryan Robinson
CFO & Treasurer1.8yrsUS$1.37m0%
$ 0
W. Middlekauff
Chief Business Officerno dataUS$582.25k0.27%
$ 1.3m
Susan Jones
Chief Technology Officerno datano datano data
Kimberly Piorkowski
Vice President of Peopleno datano datano data
Kevin Johnson
Chief Regulatory Officerno dataUS$886.62k0.23%
$ 1.1m
Dora Rau
Senior VP & Head of Qualityno datano datano data
Gerhard Hagn
Senior VP and Head of Commercial & Business Development1.8yrsno datano data
Emil deGoma
Senior Vice President of Medical Researchno datano datano data
Kristine Erickson
VP & TA Head of Ophthalmology1.5yrsno datano data
John Walsh
VP & Head of Medical Affairsno datano datano data
Famina Hemani
VP & Head of Pharmacovigilanceno datano datano data
1.8yrs
Average Tenure
60yo
Average Age

Experienced Management: TRML's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sandeep Kulkarni
Co-Founderno dataUS$848.25k2.87%
$ 13.9m
Mark McDade
Independent Directorno dataUS$152.33k0.0020%
$ 9.8k
Clay Siegall
Independent Chairman1.6yrsUS$230.13k0%
$ 0
Caley Castelein
Independent Directorno dataUS$154.33k3.79%
$ 18.4m
Sapna Srivastava
Independent Directorno dataUS$157.83k0.0020%
$ 9.8k
Deepak Bhatt
Chairman of Cardiovascular Scientific Advisory Boardless than a yearno datano data
Aaron Kantoff
Independent Directorno dataUS$154.83k0.18%
$ 856.1k
Michael Szarek
Member of Cardiovascular Scientific Advisory Boardless than a yearno datano data
Parvinder Thiara
Independent Directorno dataUS$145.38k0.33%
$ 1.6m
Joshua Beckman
Member of Cardiovascular Scientific Advisory Boardless than a yearno datano data
Marc Bonaca
Member of Cardiovascular Scientific Advisory Boardless than a yearno datano data
Robin Choudhury
Member of Cardiovascular Scientific Advisory Boardless than a yearno datano data
0.8yrs
Average Tenure
54yo
Average Age

Experienced Board: TRML's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/23 12:25
End of Day Share Price 2025/07/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tourmaline Bio, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Etzer DaroutBMO Capital Markets Equity Research
Joshua SchimmerCantor Fitzgerald & Co.